Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

Also called NCT07610174

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 160 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07610174
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07610174. Randomized; single masking; primary purpose treatment. Start 2025-06-02 (actual); primary completion 2026-04-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves
Acronym
SYNCARDIA-HF
Condition
Heart Failure
Condition
Heart Valve Prosthesis
Intervention (Drug)
semaglutide
Intervention (Drug)
Dapagliflozin (10mg Tab)
Lead sponsor
Kafrelsheikh University (class: other)

Record details

Record id
cardio:ct-nct07610174
Content hash
0f3a45b011de7de48ec332f827e1d71dfc814a0b2a916072b54cab65907ec207